{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:03:47Z","timestamp":1791464627069,"version":"4.3.4"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"DOI":"10.1186\/s11658-026-00995-9","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:44:33Z","timestamp":1784994273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ADAR-mediated RNA editing in CNS disorders: from pathogenic mechanisms to therapeutic opportunities"],"prefix":"10.1186","volume":"31","author":[{"given":"Fushuang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongli","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"5","key":"995_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","volume":"9","author":"M Simonato","year":"2013","unstructured":"Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, et\u00a0al. Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013;9(5):277\u201391.","journal-title":"Nat Rev Neurol"},{"key":"995_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.canlet.2017.09.036","volume":"411","author":"C Wang","year":"2017","unstructured":"Wang C, Zou J, Ma X, Wang E, Peng G. Mechanisms and implications of ADAR-mediated RNA editing in cancer. Cancer Lett. 2017;411:27\u201334.","journal-title":"Cancer Lett"},{"issue":"3","key":"995_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tig.2015.12.005","volume":"32","author":"M Behm","year":"2016","unstructured":"Behm M, \u00d6hman M. RNA editing: a contributor to neuronal dynamics in the mammalian brain. Trends Genet. 2016;32(3):165\u201375.","journal-title":"Trends Genet"},{"issue":"1","key":"995_CR4","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1038\/s41467-021-25790-2","volume":"12","author":"S Jimeno","year":"2021","unstructured":"Jimeno S, Prados-Carvajal R, Fern\u00e1ndez-\u00c1vila MJ, Silva S, Silvestris DA, Endara-Coll M, et\u00a0al. ADAR-mediated RNA editing of DNA: RNA hybrids is required for DNA double strand break repair. Nat Commun. 2021;12(1):5512.","journal-title":"Nat Commun"},{"issue":"7","key":"995_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/15476286.2020.1867797","volume":"18","author":"Y Yang","year":"2021","unstructured":"Yang Y, Okada S, Sakurai M. Adenosine-to-inosine RNA editing in neurological development and disease. RNA Biol. 2021;18(7):999\u20131013.","journal-title":"RNA Biol"},{"issue":"1","key":"995_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70208","volume":"31","author":"L Cheng","year":"2025","unstructured":"Cheng L, Liu Z, Shen C, Xiong Y, Shin SY, Hwang Y, et\u00a0al. A wonderful journey: the diverse roles of adenosine deaminase action on RNA 1 (ADAR 1) in central nervous system diseases. CNS Neurosci Ther. 2025;31(1):e70208.","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"995_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/pr6050042","volume":"6","author":"JT Roberts","year":"2018","unstructured":"Roberts JT, Patterson DG, King VM, Amin SV, Polska CJ, Houserova D, et\u00a0al. ADAR mediated RNA editing modulates microRNA targeting in human breast cancer. Processes. 2018;6(5):42.","journal-title":"Processes"},{"issue":"1","key":"995_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/nar\/gky1163","volume":"47","author":"K Licht","year":"2019","unstructured":"Licht K, Hartl M, Amman F, Anrather D, Janisiw MP, Jantsch MF. Inosine induces context-dependent recoding and translational stalling. Nucleic Acids Res. 2019;47(1):3\u201314.","journal-title":"Nucleic Acids Res"},{"issue":"22","key":"995_CR9","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1021\/acs.accounts.3c00433","volume":"56","author":"LP Keegan","year":"2023","unstructured":"Keegan LP, Hajji K, O\u2019Connell MA. Adenosine deaminase acting on RNA (ADAR) enzymes: a journey from weird to wondrous. Acc Chem Res. 2023;56(22):3165\u201374.","journal-title":"Acc Chem Res"},{"issue":"886","key":"995_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adr1442","volume":"18","author":"L Peterson","year":"2025","unstructured":"Peterson L, Coca R, Parikh S, McCarthy K, Man H-Y. ADAR2-mediated Q\/R editing of GluA2 in homeostatic synaptic plasticity. Sci Signal. 2025;18(886):eadr1442.","journal-title":"Sci Signal"},{"key":"995_CR11","doi-asserted-by":"crossref","unstructured":"Min DJ, Lee S, Lee Y-s, Cho J. Two codes of RNA editing by deamination in human diseases. Experimental & Molecular Medicine. 2026:1\u201314.","DOI":"10.1038\/s12276-025-01633-8"},{"issue":"7","key":"995_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/15476286.2020.1867797","volume":"18","author":"Y Yang","year":"2021","unstructured":"Yang Y, Okada S, Sakurai M. Adenosine-to-inosine RNA editing in neurological development and disease. RNA Biol. 2021;18(7):999\u20131013.","journal-title":"RNA Biol"},{"issue":"4","key":"995_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27041858","volume":"27","author":"L Borkiewicz","year":"2026","unstructured":"Borkiewicz L. Evolution of engineered ADAR-based RNA editing systems. Int J Mol Sci. 2026;27(4):1858.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"995_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70389","volume":"6","author":"JM Li","year":"2025","unstructured":"Li JM, Huang J, Liao Y, Hu T, Wang CL, Zhang WZ, et\u00a0al. Gene and RNA editing: revolutionary approaches to treating diseases. MedComm. 2025;6(10):e70389.","journal-title":"MedComm"},{"issue":"3","key":"995_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s44318-024-00352-6","volume":"44","author":"Y Li","year":"2025","unstructured":"Li Y, Sun S. RNA dysregulation in neurodegenerative diseases. EMBO J. 2025;44(3):613.","journal-title":"EMBO J"},{"issue":"4","key":"995_CR16","doi-asserted-by":"publisher","first-page":"26298","DOI":"10.31083\/FBL26298","volume":"30","author":"A Modestov","year":"2025","unstructured":"Modestov A, Buzdin A, Suntsova M. Unveiling RNA editing by ADAR and APOBEC protein gene families. Frontiers in Bioscience-Landmark. 2025;30(4):26298.","journal-title":"Frontiers in Bioscience-Landmark"},{"key":"995_CR17","doi-asserted-by":"crossref","unstructured":"Collins JM, Yu F, Zhang Y, Wang D. Knockdown of RNA editing proteins reshapes the HepaRG transcriptome and pharmacogene expression. Scientific Reports. 2026.","DOI":"10.1038\/s41598-026-43323-z"},{"issue":"1","key":"995_CR18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1146\/annurev.biochem.71.110601.135501","volume":"71","author":"BL Bass","year":"2002","unstructured":"Bass BL. RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem. 2002;71(1):817\u201346.","journal-title":"Annu Rev Biochem"},{"key":"995_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.omtn.2019.12.042","volume":"19","author":"G Aquino-Jarquin","year":"2020","unstructured":"Aquino-Jarquin G. Novel engineered programmable systems for ADAR-mediated RNA editing. Molecular Therapy Nucleic Acids. 2020;19:1065\u201372.","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"995_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102284","author":"AJ Fisher","year":"2024","unstructured":"Fisher AJ, Beal PA. Structural perspectives on adenosine to inosine RNA editing by ADARs. Mol Ther Nucleic Acids. 2024. https:\/\/doi.org\/10.1016\/j.omtn.2024.102284.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"995_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/wrna.1319","volume":"7","author":"SN Deffit","year":"2016","unstructured":"Deffit SN, Hundley HA. To edit or not to edit: regulation of ADAR editing specificity and efficiency. Wiley Interdisciplinary Reviews: RNA. 2016;7(1):113\u201327.","journal-title":"Wiley Interdisciplinary Reviews: RNA"},{"issue":"1","key":"995_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43633-0","volume":"14","author":"MS Zambrano-Mila","year":"2023","unstructured":"Zambrano-Mila MS, Witzenberger M, Rosenwasser Z, Uzonyi A, Nir R, Ben-Aroya S, et\u00a0al. Dissecting the basis for differential substrate specificity of ADAR1 and ADAR2. Nat Commun. 2023;14(1):8212.","journal-title":"Nat Commun"},{"issue":"9","key":"995_CR23","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00439-017-1837-0","volume":"136","author":"A Gallo","year":"2017","unstructured":"Gallo A, Vukic D, Michal\u00edk D, O\u2019connell MA, Keegan LP. ADAR RNA editing in human disease; more to it than meets the I. Hum Genet. 2017;136(9):1265\u201378.","journal-title":"Hum Genet"},{"issue":"4","key":"995_CR24","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.3390\/biom5042338","volume":"5","author":"N Mannion","year":"2015","unstructured":"Mannion N, Arieti F, Gallo A, Keegan LP, O\u2019Connell MA. New insights into the biological role of mammalian ADARs; the RNA editing proteins. Biomolecules. 2015;5(4):2338\u201362.","journal-title":"Biomolecules"},{"issue":"13","key":"995_CR25","doi-asserted-by":"publisher","first-page":"7424","DOI":"10.3390\/ijms25137424","volume":"25","author":"YA Bernal","year":"2024","unstructured":"Bernal YA, Dur\u00e1n E, Solar I, Sagredo EA, Armis\u00e9n R. ADAR-mediated A> I (G) RNA editing in the genotoxic drug response of breast cancer. Int J Mol Sci. 2024;25(13):7424.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"995_CR26","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1091\/mbc.e05-06-0536","volume":"16","author":"JM Desterro","year":"2005","unstructured":"Desterro JM, Keegan LP, Jaffray E, Hay RT, O\u2019Connell MA, Carmo-Fonseca M. SUMO-1 modification alters ADAR1 editing activity. Mol Biol Cell. 2005;16(11):5115\u201326.","journal-title":"Mol Biol Cell"},{"issue":"11","key":"995_CR27","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1124\/dmd.123.001396","volume":"51","author":"JM Collins","year":"2023","unstructured":"Collins JM, Wang D. A comprehensive evaluation of the effects of RNA-editing proteins ADAR and ADARB1 on the expression of the drug-metabolizing enzymes in HepaRG cells. Drug Metab Dispos. 2023;51(11):1508\u201314.","journal-title":"Drug Metab Dispos"},{"key":"995_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fbioe.2015.00037","volume":"3","author":"G Nigita","year":"2015","unstructured":"Nigita G, Veneziano D, Ferro A. A-to-I RNA editing: current knowledge sources and computational approaches with special emphasis on non-coding RNA molecules. Frontiers in bioengineering and biotechnology. 2015;3:37.","journal-title":"Frontiers in bioengineering and biotechnology"},{"issue":"14","key":"995_CR29","doi-asserted-by":"publisher","first-page":"7958","DOI":"10.1093\/nar\/gkaa532","volume":"48","author":"AS Thuy-Boun","year":"2020","unstructured":"Thuy-Boun AS, Thomas JM, Grajo HL, Palumbo CM, Park S, Nguyen LT, et\u00a0al. Asymmetric dimerization of adenosine deaminase acting on RNA facilitates substrate recognition. Nucleic Acids Res. 2020;48(14):7958\u201372.","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"995_CR30","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1021\/acs.accounts.3c00390","volume":"56","author":"HG Mendoza","year":"2023","unstructured":"Mendoza HG, Beal PA. Chemical modifications in RNA: elucidating the chemistry of dsRNA-specific adenosine deaminases (ADARs). Acc Chem Res. 2023;56(18):2489\u201399.","journal-title":"Acc Chem Res"},{"key":"995_CR31","doi-asserted-by":"crossref","unstructured":"Cho D-SC, Yang W, Lee JT, Shiekhattar R, Murray JM, Nishikura K. Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. Journal of Biological Chemistry. 2003;278(19):17093\u2013102.","DOI":"10.1074\/jbc.M213127200"},{"issue":"5","key":"995_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nsmb.3203","volume":"23","author":"MM Matthews","year":"2016","unstructured":"Matthews MM, Thomas JM, Zheng Y, Tran K, Phelps KJ, Scott AI, et\u00a0al. Structures of human ADAR2 bound to dsRNA reveal base-flipping mechanism and basis for site selectivity. Nat Struct Mol Biol. 2016;23(5):426\u201333.","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"995_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.chembiol.2018.10.025","volume":"26","author":"LR Monteleone","year":"2019","unstructured":"Monteleone LR, Matthews MM, Palumbo CM, Thomas JM, Zheng Y, Chiang Y, et\u00a0al. A bump-hole approach for directed RNA editing. Cell Chem Biol. 2019;26(2):269-77. e5.","journal-title":"Cell Chem Biol"},{"issue":"1","key":"995_CR34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1186\/s12864-023-09778-4","volume":"24","author":"B Wales-McGrath","year":"2023","unstructured":"Wales-McGrath B, Mercer H, Piontkivska H. Changes in ADAR RNA editing patterns in CMV and ZIKV congenital infections. BMC Genomics. 2023;24(1):685.","journal-title":"BMC Genomics"},{"issue":"12","key":"995_CR35","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.tig.2019.09.004","volume":"35","author":"M Jain","year":"2019","unstructured":"Jain M, Jantsch MF, Licht K. The editor\u2019s I on disease development. Trends Genet. 2019;35(12):903\u201313.","journal-title":"Trends Genet"},{"issue":"6791","key":"995_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/35017558","volume":"406","author":"M Higuchi","year":"2000","unstructured":"Higuchi M, Maas S, Single FN, Hartner J, Rozov A, Burnashev N, et\u00a0al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406(6791):78\u201381.","journal-title":"Nature"},{"key":"995_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gm508","volume":"5","author":"W Slotkin","year":"2013","unstructured":"Slotkin W, Nishikura K. Adenosine-to-inosine RNA editing and human disease. Genome Med. 2013;5:1\u201313.","journal-title":"Genome Med"},{"issue":"1","key":"995_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41398-021-01252-7","volume":"11","author":"G Warhaftig","year":"2021","unstructured":"Warhaftig G, Sokolik CM, Khermesh K, Lichtenstein Y, Barak M, Bareli T, et\u00a0al. RNA editing of the 5-HT2C receptor in the central nucleus of the amygdala is involved in resilience behavior. Transl Psychiatry. 2021;11(1):137.","journal-title":"Transl Psychiatry"},{"key":"995_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1338065","volume":"16","author":"LT Milham","year":"2024","unstructured":"Milham LT, Morris GP, Konen LM, Rentsch P, Avgan N, Vissel B. Quantification of AMPA receptor subunits and RNA editing-related proteins in the J20 mouse model of Alzheimer\u2019s disease by capillary western blotting. Front Mol Neurosci. 2024;16:1338065.","journal-title":"Front Mol Neurosci"},{"issue":"2","key":"995_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/hmg\/ddr461","volume":"21","author":"G Silberberg","year":"2012","unstructured":"Silberberg G, Lundin D, Navon R, \u00d6hman M. Deregulation of the A-to-I RNA editing mechanism in psychiatric disorders. Hum Mol Genet. 2012;21(2):311\u201321.","journal-title":"Hum Mol Genet"},{"key":"995_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-3-319-89689-2_3","volume-title":"RNA metabolism in neurodegenerative diseases","author":"I Lorenzini","year":"2018","unstructured":"Lorenzini I, Moore S, Sattler R. RNA editing deficiency in neurodegeneration. In: RNA metabolism in neurodegenerative diseases. 2018. p. 63\u201383."},{"key":"995_CR42","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.9755","volume":"8","author":"V Patil","year":"2020","unstructured":"Patil V, Pal J, Mahalingam K, Somasundaram K. Global RNA editome landscape discovers reduced RNA editing in glioma: loss of editing of gamma-amino butyric acid receptor alpha subunit 3 (GABRA3) favors glioma migration and invasion. PeerJ. 2020;8:e9755.","journal-title":"PeerJ"},{"issue":"1","key":"995_CR43","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1080\/15476286.2024.2414156","volume":"21","author":"W Liu","year":"2024","unstructured":"Liu W, Wu Y, Zhang T, Sun X, Guo D, Yang Z. The role of dsRNA A-to-I editing catalyzed by ADAR family enzymes in the pathogeneses. RNA Biol. 2024;21(1):1128\u201345.","journal-title":"RNA Biol"},{"issue":"6","key":"995_CR44","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1074\/jbc.M311347200","volume":"279","author":"JC Hartner","year":"2004","unstructured":"Hartner JC, Schmittwolf C, Kispert A, M\u00fcller AM, Higuchi M, Seeburg PH. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J Biol Chem. 2004;279(6):4894\u2013902.","journal-title":"J Biol Chem"},{"issue":"1","key":"995_CR45","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.1038\/ncomms10512","volume":"7","author":"J Robinson","year":"2016","unstructured":"Robinson J, Paluch J, Dickman D, Joiner W. ADAR-mediated RNA editing suppresses sleep by acting as a brake on glutamatergic synaptic plasticity. Nat Commun. 2016;7(1):10512.","journal-title":"Nat Commun"},{"key":"995_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.mcn.2012.10.009","volume":"52","author":"C Maldonado","year":"2013","unstructured":"Maldonado C, Alicea D, Gonzalez M, Bykhovskaia M, Marie B. Adar is essential for optimal presynaptic function. Mol Cell Neurosci. 2013;52:173\u201380.","journal-title":"Mol Cell Neurosci"},{"issue":"1","key":"995_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6606-7-5","volume":"7","author":"M Kubota-Sakashita","year":"2014","unstructured":"Kubota-Sakashita M, Iwamoto K, Bundo M, Kato T. A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia. Mol Brain. 2014;7(1):5.","journal-title":"Mol Brain"},{"issue":"11","key":"995_CR48","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.2414","volume":"44","author":"GI Rice","year":"2012","unstructured":"Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szynkiewicz M, et\u00a0al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet. 2012;44(11):1243\u20138.","journal-title":"Nat Genet"},{"issue":"7","key":"995_CR49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/jmedgenet-2020-107048","volume":"58","author":"R Maroofian","year":"2021","unstructured":"Maroofian R, Sedm\u00edk J, Mazaheri N, Scala M, Zaki MS, Keegan LP, et\u00a0al. Biallelic variants in ADARB1, encoding a dsRNA-specific adenosine deaminase, cause a severe developmental and epileptic encephalopathy. J Med Genet. 2021;58(7):495\u2013504.","journal-title":"J Med Genet"},{"issue":"4","key":"995_CR50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ajhg.2020.02.015","volume":"106","author":"TY Tan","year":"2020","unstructured":"Tan TY, Sedm\u00edk J, Fitzgerald MP, Halevy RS, Keegan LP, Helbig I, et\u00a0al. Bi-allelic ADARB1 variants associated with microcephaly, intellectual disability, and seizures. The American Journal of Human Genetics. 2020;106(4):467\u201383.","journal-title":"The American Journal of Human Genetics"},{"key":"995_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fnmol.2012.00034","volume":"5","author":"A Wright","year":"2012","unstructured":"Wright A, Vissel B. The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain. Front Mol Neurosci. 2012;5:34.","journal-title":"Front Mol Neurosci"},{"issue":"6301","key":"995_CR52","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1126\/science.aag3194","volume":"353","author":"ML Estes","year":"2016","unstructured":"Estes ML, McAllister AK. Maternal immune activation: Implications for neuropsychiatric disorders. Science. 2016;353(6301):772\u20137.","journal-title":"Science"},{"issue":"1","key":"995_CR53","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1038\/s41467-020-19048-6","volume":"11","author":"H Tsivion-Visbord","year":"2020","unstructured":"Tsivion-Visbord H, Kopel E, Feiglin A, Sofer T, Barzilay R, Ben-Zur T, et\u00a0al. Increased RNA editing in maternal immune activation model of neurodevelopmental disease. Nat Commun. 2020;11(1):5236.","journal-title":"Nat Commun"},{"issue":"1","key":"995_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12915-020-0747-0","volume":"18","author":"A Khan","year":"2020","unstructured":"Khan A, Paro S, McGurk L, Sambrani N, Hogg MC, Brindle J, et\u00a0al. Membrane and synaptic defects leading to neurodegeneration in Adar mutant Drosophila are rescued by increased autophagy. BMC Biol. 2020;18(1):15.","journal-title":"BMC Biol"},{"issue":"3","key":"995_CR55","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1152\/physrev.00036.2006","volume":"87","author":"MF Mehler","year":"2007","unstructured":"Mehler MF, Mattick JS. Noncoding RNAs and RNA editing in brain development, functional diversification, and neurological disease. Physiol Rev. 2007;87(3):799\u2013823.","journal-title":"Physiol Rev"},{"key":"995_CR56","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fgene.2012.00326","volume":"3","author":"M Singh","year":"2013","unstructured":"Singh M. Dysregulated A to I RNA editing and non-coding RNAs in neurodegeneration. Front Genet. 2013;3:326.","journal-title":"Front Genet"},{"issue":"1","key":"995_CR57","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/s41467-022-30531-0","volume":"13","author":"WH Cuddleston","year":"2022","unstructured":"Cuddleston WH, Li J, Fan X, Kozenkov A, Lalli M, Khalique S, et\u00a0al. Cellular and genetic drivers of RNA editing variation in the human brain. Nat Commun. 2022;13(1):2997.","journal-title":"Nat Commun"},{"issue":"6","key":"995_CR58","doi-asserted-by":"publisher","first-page":"1800239","DOI":"10.1002\/bies.201800239","volume":"41","author":"H Piontkivska","year":"2019","unstructured":"Piontkivska H, Plonski NM, Miyamoto MM, Wayne ML. Explaining pathogenicity of congenital Zika and Guillain-Barr\u00e9 syndromes: does dysregulation of RNA editing play a role? BioEssays. 2019;41(6):1800239.","journal-title":"BioEssays"},{"issue":"8","key":"995_CR59","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1134\/S0006297924080078","volume":"89","author":"VV Kudriavskii","year":"2024","unstructured":"Kudriavskii VV, Goncharov AO, Eremeev AV, Ruchko ES, Veselovsky VA, Klimina KM, et\u00a0al. RNA editing by ADAR adenosine deaminases in the cell models of CAG repeat expansion diseases: significant effect of differentiation from stem cells into brain organoids in the absence of substantial influence of CAG repeats on the level of editing. Biochem Mosc. 2024;89(8):1474\u201389.","journal-title":"Biochem Mosc"},{"issue":"1","key":"995_CR60","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41593-023-01499-x","volume":"27","author":"W-K Li","year":"2024","unstructured":"Li W-K, Zhang S-Q, Peng W-L, Shi Y-H, Yuan B, Yuan Y-T, et\u00a0al. Whole-brain in vivo base editing reverses behavioral changes in Mef2c-mutant mice. Nat Neurosci. 2024;27(1):116\u201328.","journal-title":"Nat Neurosci"},{"issue":"1","key":"995_CR61","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1038\/s41467-021-27204-9","volume":"12","author":"Y Ma","year":"2021","unstructured":"Ma Y, Dammer EB, Felsky D, Duong DM, Klein H-U, White CC, et\u00a0al. Atlas of RNA editing events affecting protein expression in aged and Alzheimer\u2019s disease human brain tissue. Nat Commun. 2021;12(1):7035.","journal-title":"Nat Commun"},{"issue":"5","key":"995_CR62","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac238","volume":"4","author":"PS Crooke III","year":"2022","unstructured":"Crooke PS III, Tossberg JT, Heinrich RM, Porter KP, Aune TM. Reduced RNA adenosine-to-inosine editing in hippocampus vasculature associated with Alzheimer\u2019s disease. Brain Commun. 2022;4(5):fcac238.","journal-title":"Brain Commun"},{"key":"995_CR63","doi-asserted-by":"publisher","DOI":"10.1177\/13872877241313054","author":"PS Crooke 3rd","year":"2025","unstructured":"Crooke PS 3rd, Tossberg JT, Aune TM. Increased unedited Alu RNA patterns found in cortex extracellular vesicles in Alzheimer\u2019s disease resemble hippocampus vasculature Alu RNA editing patterns but not cortex Alu RNA editing patterns. J Alzheimers Dis. 2025. https:\/\/doi.org\/10.1177\/13872877241313054.","journal-title":"J Alzheimers Dis"},{"key":"995_CR64","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2022.36.S1.R3769","author":"CM McEntee","year":"2022","unstructured":"McEntee CM, Cavalier AN, LaRocca TJ. ADAR dysfunction in brain aging and Alzheimer\u2019s disease. FASEB J. 2022. https:\/\/doi.org\/10.1096\/fasebj.2022.36.S1.R3769.","journal-title":"FASEB J"},{"key":"995_CR65","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00109-004-0599-z","volume":"83","author":"S Kwak","year":"2005","unstructured":"Kwak S, Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med. 2005;83:110\u201320.","journal-title":"J Mol Med"},{"issue":"1","key":"995_CR66","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10020-024-00863-2","volume":"30","author":"K Karagianni","year":"2024","unstructured":"Karagianni K, Dafou D, Xanthopoulos K, Sklaviadis T, Kanata E. RNA editing regulates glutamatergic synapses in the frontal cortex of a molecular subtype of amyotrophic lateral sclerosis. Mol Med. 2024;30(1):101.","journal-title":"Mol Med"},{"key":"995_CR67","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-019-01999-w","volume":"138","author":"S Moore","year":"2019","unstructured":"Moore S, Alsop E, Lorenzini I, Starr A, Rabichow BE, Mendez E, et\u00a0al. ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS\/FTD. Acta Neuropathol. 2019;138:49\u201365.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"995_CR68","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s00415-023-12053-x","volume":"271","author":"W Li","year":"2024","unstructured":"Li W, Wu H, Li J, Wang Z, Cai M, Liu X, et\u00a0al. Transcriptomic analysis reveals associations of blood-based A-to-I editing with Parkinson\u2019s disease. J Neurol. 2024;271(2):976\u201385.","journal-title":"J Neurol"},{"key":"995_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/genes14040919","author":"S Wu","year":"2023","unstructured":"Wu S, Xue Q, Qin X, Wu X, Kim P, Chyr J, et\u00a0al. The potential regulation of A-to-I RNA editing on genes in Parkinson\u2019s disease. Genes (Basel). 2023. https:\/\/doi.org\/10.3390\/genes14040919.","journal-title":"Genes (Basel)"},{"issue":"1","key":"995_CR70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/genes13010014","volume":"13","author":"DV Pozdyshev","year":"2021","unstructured":"Pozdyshev DV, Zharikova AA, Medvedeva MV, Muronetz VI. Differential analysis of A-to-I mRNA edited sites in Parkinson\u2019s disease. Genes. 2021;13(1):14.","journal-title":"Genes"},{"key":"995_CR71","doi-asserted-by":"crossref","unstructured":"Mercer HM, Nair AM, Tariq A, Piontkivska H. The role of ADAR editing and nonsense-mediated decay in Parkinson\u2019s Disease. bioRxiv. 2024:2024.05. 17.594716.","DOI":"10.1101\/2024.05.17.594716"},{"issue":"15","key":"995_CR72","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp8504","volume":"11","author":"K D\u2019Sa","year":"2025","unstructured":"D\u2019Sa K, Choi ML, Wagen AZ, Set\u00f3-Salvia N, Kopach O, Evans JR, et\u00a0al. Astrocytic RNA editing regulates the host immune response to alpha-synuclein. Sci Adv. 2025;11(15):eadp8504.","journal-title":"Sci Adv"},{"key":"995_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110845","volume":"110","author":"Z Song","year":"2023","unstructured":"Song Z, Ding Q, Yang Y. Orchestration of a blood-derived and ADARB1-centred network in Alzheimer\u2019s and Parkinson\u2019s disease. Cell Signal. 2023;110:110845.","journal-title":"Cell Signal"},{"key":"995_CR74","doi-asserted-by":"crossref","unstructured":"Belur NR, Bustos BI, Lubbe SJ, Mazzulli JR. Nuclear aggregates of NONO\/SFPQ and A-to-I-edited RNA in Parkinson\u2019s disease and dementia with Lewy bodies. Neuron. 2024;112(15):2558\u201380. e13.","DOI":"10.1016\/j.neuron.2024.05.003"},{"key":"995_CR75","doi-asserted-by":"crossref","unstructured":"Tossberg JT, Heinrich RM, Farley VM, Crooke III PS, Aune TM. A-to-I RNA editing of Alu dsRNAs is markedly decreased in MS; unedited Alu dsRNAs but not edited Alu dsRNAs are potent activators of pro-inflammatory transcriptional responses. Journal of immunology (Baltimore, Md: 1950). 2020;205(10):2606.","DOI":"10.4049\/jimmunol.2000384"},{"issue":"03","key":"995_CR76","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1055\/s-0043-1771001","volume":"10","author":"F Fakhr","year":"2023","unstructured":"Fakhr F, Shaygannejad V, Khorrami M, Saberi L, Mirmosayyeb O, Sadeghi E, et\u00a0al. ADAR expression and single nucleotide variants in multiple sclerosis patients affect the response to interferon beta therapy. Global Medical Genetics. 2023;10(03):164\u201371.","journal-title":"Global Medical Genetics"},{"issue":"22","key":"995_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223582","volume":"11","author":"D Dafou","year":"2022","unstructured":"Dafou D, Kanata E, Pettas S, Bekas N, Dimitriadis A, Kempapidou G, et\u00a0al. RNA editing alterations define disease manifestations in the progression of experimental autoimmune encephalomyelitis (EAE). Cells. 2022;11(22):3582.","journal-title":"Cells"},{"key":"995_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102903","volume":"67","author":"D Cai","year":"2023","unstructured":"Cai D, Fraunfelder M, Fujise K, Chen S-Y. ADAR1 exacerbates ischemic brain injury via astrocyte-mediated neuron apoptosis. Redox Biol. 2023;67:102903.","journal-title":"Redox Biol"},{"issue":"1","key":"995_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-025-08841-5","volume":"27","author":"G-P Wang","year":"2025","unstructured":"Wang G-P, Li W-J, Li Y, Ma M-X, Guo K-K. ADAR1 promotes NUPR1 A-to-I RNA editing to exacerbate ischemic brain injury by microglia mediated neuroinflammation. NeuroMol Med. 2025;27(1):1\u201315.","journal-title":"NeuroMol Med"},{"issue":"5","key":"995_CR80","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.immuni.2023.03.021","volume":"56","author":"A Gatsiou","year":"2023","unstructured":"Gatsiou A, Tual-Chalot S, Napoli M, Ortega-Gomez A, Regen T, Badolia R, et\u00a0al. The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation. Immunity. 2023;56(5):979.","journal-title":"Immunity"},{"issue":"3","key":"995_CR81","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/hmg\/ddae172","volume":"34","author":"M Choudhury","year":"2025","unstructured":"Choudhury M, Yamamoto R, Xiao X. Genetic architecture of RNA editing, splicing and gene expression in schizophrenia. Hum Mol Genet. 2025;34(3):277\u201390.","journal-title":"Hum Mol Genet"},{"key":"995_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-6606-7-5","volume":"7","author":"M Kubota-Sakashita","year":"2014","unstructured":"Kubota-Sakashita M, Iwamoto K, Bundo M, Kato T. A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia. Mol Brain. 2014;7:1\u201314.","journal-title":"Mol Brain"},{"issue":"4","key":"995_CR83","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3109\/15622975.2014.1000374","volume":"16","author":"J Karanovi\u0107","year":"2015","unstructured":"Karanovi\u0107 J, \u0160vikovi\u0107 S, Pantovi\u0107 M, Durica S, Braju\u0161kovi\u0107 G, Damjanovi\u0107 A, et\u00a0al. Joint effect of ADARB1 gene, HTR2C gene and stressful life events on suicide attempt risk in patients with major psychiatric disorders. The World Journal of Biological Psychiatry. 2015;16(4):261\u201371.","journal-title":"The World Journal of Biological Psychiatry"},{"issue":"1","key":"995_CR84","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41398-021-01377-9","volume":"11","author":"N Salvetat","year":"2021","unstructured":"Salvetat N, Chimienti F, Cayzac C, Dubuc B, Checa-Robles F, Dupre P, et\u00a0al. Phosphodiesterase 8A to discriminate in blood samples depressed patients and suicide attempters from healthy controls based on A-to-I RNA editing modifications. Transl Psychiatry. 2021;11(1):255.","journal-title":"Transl Psychiatry"},{"key":"995_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2020.113087","volume":"402","author":"X Zhang","year":"2021","unstructured":"Zhang X, Xue Y, Li J, Xu H, Yan W, Zhao Z, et\u00a0al. The involvement of ADAR1 in antidepressant action by regulating BDNF via miR-432. Behav Brain Res. 2021;402:113087.","journal-title":"Behav Brain Res"},{"key":"995_CR86","doi-asserted-by":"crossref","unstructured":"Fritzell K, Xu L-D, Lagergren J, \u00d6hman M. ADARs and editing: the role of A-to-I RNA modification in cancer progression. Seminars in cell & developmental biology; 2018: Elsevier.","DOI":"10.1016\/j.semcdb.2017.11.018"},{"issue":"1","key":"995_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/genes10010012","volume":"10","author":"L-D Xu","year":"2018","unstructured":"Xu L-D, \u00d6hman M. ADAR1 editing and its role in cancer. Genes (Basel). 2018;10(1):12.","journal-title":"Genes (Basel)"},{"issue":"9","key":"995_CR88","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.tibs.2021.02.002","volume":"46","author":"J Quin","year":"2021","unstructured":"Quin J, Sedm\u00edk J, Vuki\u0107 D, Khan A, Keegan LP, O\u2019Connell MA. ADAR RNA modifications, the epitranscriptome and innate immunity. Trends Biochem Sci. 2021;46(9):758\u201371.","journal-title":"Trends Biochem Sci"},{"issue":"7737","key":"995_CR89","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41586-018-0768-9","volume":"565","author":"JJ Ishizuka","year":"2019","unstructured":"Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, et\u00a0al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature. 2019;565(7737):43\u20138.","journal-title":"Nature"},{"issue":"1","key":"995_CR90","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70168","volume":"31","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Guo H, Bu J, Wang W, Wang L, Liu Z, et\u00a0al. ADAR1 promotes the progression and temozolomide resistance of glioma through p62-mediated selective autophagy. CNS Neurosci Ther. 2025;31(1):e70168.","journal-title":"CNS Neurosci Ther"},{"key":"995_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-021-02271-9","volume":"22","author":"V Tassinari","year":"2021","unstructured":"Tassinari V, Cesarini V, Tomaselli S, Ianniello Z, Silvestris DA, Ginistrelli LC, et\u00a0al. ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. Genome Biol. 2021;22:1\u201322.","journal-title":"Genome Biol"},{"issue":"8","key":"995_CR92","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3390\/biom12081142","volume":"12","author":"V Cesarini","year":"2022","unstructured":"Cesarini V, Silvestris DA, Galeano F, Tassinari V, Martini M, Locatelli F, et\u00a0al. ADAR2 protein is associated with overall survival in GBM patients and its decrease triggers the anchorage-independent cell growth signature. Biomolecules. 2022;12(8):1142.","journal-title":"Biomolecules"},{"issue":"1","key":"995_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11658-024-00680-9","volume":"30","author":"Z Cui","year":"2025","unstructured":"Cui Z, Liu X, Lin H, Wang D, Liu Y, Ruan X, et\u00a0al. Effect of SNORD113-3\/ADAR2 on glycolipid metabolism in glioblastoma via A-to-I editing of PHKA2. Cell Mol Biol Lett. 2025;30(1):1\u201328.","journal-title":"Cell Mol Biol Lett"},{"issue":"4","key":"995_CR94","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/nar\/gkx1257","volume":"46","author":"V Cesarini","year":"2018","unstructured":"Cesarini V, Silvestris DA, Tassinari V, Tomaselli S, Alon S, Eisenberg E, et\u00a0al. ADAR2\/miR-589-3p axis controls glioblastoma cell migration\/invasion. Nucleic Acids Res. 2018;46(4):2045\u201359.","journal-title":"Nucleic Acids Res"},{"key":"995_CR95","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.brainresbull.2022.04.005","volume":"186","author":"J Luo","year":"2022","unstructured":"Luo J, Bai R, Liu Y, Bi H, Shi X, Qu C. Long non-coding RNA ATXN8OS promotes ferroptosis and inhibits the temozolomide-resistance of gliomas through the ADAR\/GLS2 pathway. Brain Res Bull. 2022;186:27\u201337.","journal-title":"Brain Res Bull"},{"issue":"2","key":"995_CR96","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s11064-019-02943-w","volume":"45","author":"X Lv","year":"2020","unstructured":"Lv X, Gu C, Guo S. Activation of BDNF-AS\/ADAR\/p53 positive feedback loop inhibits glioblastoma cell proliferation. Neurochem Res. 2020;45(2):508\u201318.","journal-title":"Neurochem Res"},{"issue":"6","key":"995_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2024.152855","volume":"229","author":"Q Yang","year":"2024","unstructured":"Yang Q, Li X. Pan-cancer analysis of ADAR1 with its prognostic relevance in low-grade glioma. Immunobiology. 2024;229(6):152855.","journal-title":"Immunobiology"},{"key":"995_CR98","doi-asserted-by":"publisher","first-page":"1435185","DOI":"10.3389\/fnins.2024.1435185","volume":"18","author":"Y-N Li","year":"2024","unstructured":"Li Y-N, Liang Y-P, Zhang J-Q, Li N, Wei Z-Y, Rao Y, et\u00a0al. Dynamic A-to-I RNA editing during acute neuroinflammation in sepsis-associated encephalopathy. Front Neurosci. 2024;18:1435185.","journal-title":"Front Neurosci"},{"key":"995_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.146760","volume":"1735","author":"S Jung","year":"2020","unstructured":"Jung S, Ballheimer YE, Brackmann F, Zoglauer D, Geppert C-I, Hartmann A, et\u00a0al. Seizure-induced neuronal apoptosis is related to dysregulation of the RNA-edited GluR2 subunit in the developing mouse brain. Brain Res. 2020;1735:146760.","journal-title":"Brain Res"},{"issue":"9","key":"995_CR100","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.3390\/ijms26094276","volume":"26","author":"ZZ Chong","year":"2025","unstructured":"Chong ZZ, Souayah N. Targeting gene C9orf72 pathogenesis for amyotrophic lateral sclerosis. Int J Mol Sci. 2025;26(9):4276.","journal-title":"Int J Mol Sci"},{"key":"995_CR101","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szaf016","author":"J Rainaldi","year":"2025","unstructured":"Rainaldi J, Mali P, Nourreddine S. Emerging clinical applications of ADAR based RNA editing. Stem Cells Transl Med. 2025. https:\/\/doi.org\/10.1093\/stcltm\/szaf016.","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"995_CR102","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41587-019-0178-z","volume":"37","author":"L Qu","year":"2019","unstructured":"Qu L, Yi Z, Zhu S, Wang C, Cao Z, Zhou Z, et\u00a0al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat Biotechnol. 2019;37(9):1059\u201369.","journal-title":"Nat Biotechnol"},{"key":"995_CR103","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.75555","author":"D Katrekar","year":"2022","unstructured":"Katrekar D, Xiang Y, Palmer N, Saha A, Meluzzi D, Mali P. Comprehensive interrogation of the ADAR2 deaminase domain for engineering enhanced RNA editing activity and specificity. Elife. 2022. https:\/\/doi.org\/10.7554\/eLife.75555.","journal-title":"Elife"},{"issue":"9","key":"995_CR104","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41587-019-0178-z","volume":"37","author":"L Qu","year":"2019","unstructured":"Qu L, Yi Z, Zhu S, Wang C, Cao Z, Zhou Z, et\u00a0al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat Biotechnol. 2019;37(9):1059\u201369.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"995_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/genes16010077","volume":"16","author":"M Bertoli","year":"2025","unstructured":"Bertoli M, La Via L, Barbon A. ADAR therapeutics as a new tool for personalized medicine. Genes (Basel). 2025;16(1):77.","journal-title":"Genes (Basel)"},{"issue":"3","key":"995_CR106","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41587-025-02628-6","volume":"44","author":"Y Sun","year":"2026","unstructured":"Sun Y, Cao Y, Song Y, Li J, Hou Y, Huang W, et\u00a0al. Improved RNA base editing with guide RNAs mimicking highly edited endogenous ADAR substrates. Nat Biotechnol. 2026;44(3):464\u201376.","journal-title":"Nat Biotechnol"},{"key":"995_CR107","doi-asserted-by":"crossref","unstructured":"Sun Y, Cao Y, Song Y, Li J, Hou Y, Huang W, et\u00a0al. Improved RNA base editing with guide RNAs mimicking highly edited endogenous ADAR substrates. Nature Biotechnology. 2025:1\u201313.","DOI":"10.1038\/s41587-026-03246-6"},{"issue":"6","key":"995_CR108","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.ymthe.2023.01.005","volume":"31","author":"BJ Booth","year":"2023","unstructured":"Booth BJ, Nourreddine S, Katrekar D, Savva Y, Bose D, Long TJ, et\u00a0al. RNA editing: expanding the potential of RNA therapeutics. Mol Ther. 2023;31(6):1533\u201349.","journal-title":"Mol Ther"},{"issue":"sup1","key":"995_CR109","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/15476286.2021.1983288","volume":"18","author":"HM Khosravi","year":"2021","unstructured":"Khosravi HM, Jantsch MF. Site-directed RNA editing: recent advances and open challenges. RNA Biol. 2021;18(sup1):41\u201350.","journal-title":"RNA Biol"},{"key":"995_CR110","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ymeth.2022.06.011","volume":"205","author":"Y Xiang","year":"2022","unstructured":"Xiang Y, Katrekar D, Mali P. Methods for recruiting endogenous and exogenous ADAR enzymes for site-specific RNA editing. Methods. 2022;205:158\u201366.","journal-title":"Methods"},{"key":"995_CR111","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ymeth.2018.11.016","volume":"156","author":"MF Montiel-Gonzalez","year":"2019","unstructured":"Montiel-Gonzalez MF, Quiroz JFD, Rosenthal JJ. Current strategies for site-directed RNA editing using ADARs. Methods. 2019;156:16\u201324.","journal-title":"Methods"},{"issue":"44","key":"995_CR112","doi-asserted-by":"publisher","first-page":"11166","DOI":"10.1002\/anie.201206489","volume":"51","author":"T Stafforst","year":"2012","unstructured":"Stafforst T, Schneider MF. An RNA-deaminase conjugate selectively repairs point mutations. Angew Chem Int Ed Engl. 2012;51(44):11166\u20139.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"3","key":"995_CR113","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3390\/ijms21030777","volume":"21","author":"LE Fry","year":"2020","unstructured":"Fry LE, Peddle CF, Barnard AR, McClements ME, MacLaren RE. RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences. Int J Mol Sci. 2020;21(3):777.","journal-title":"Int J Mol Sci"},{"key":"995_CR114","unstructured":"Li G, Chen G, Yuan G-H, Wei J, Ni Q, Wu J, et\u00a0al. Specific and efficient RNA A-to-I editing through cleavage of an ADAR inhibitor. Nature Biotechnology. 2025:1\u201313."},{"issue":"6","key":"995_CR115","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10142-022-00910-3","volume":"22","author":"M Li","year":"2022","unstructured":"Li M, Yan C, Jiao Y, Xu Y, Bai C, Miao R, et\u00a0al. Site-directed RNA editing by harnessing ADARs: advances and challenges. Funct Integr Genomics. 2022;22(6):1089\u2013103.","journal-title":"Funct Integr Genomics"},{"issue":"24","key":"995_CR116","doi-asserted-by":"publisher","first-page":"10529","DOI":"10.1523\/JNEUROSCI.22-24-10529.2002","volume":"22","author":"I Gurevich","year":"2002","unstructured":"Gurevich I, Englander MT, Adlersberg M, Siegal NB, Schmauss C. Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission. J Neurosci. 2002;22(24):10529\u201332.","journal-title":"J Neurosci"},{"issue":"5","key":"995_CR117","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.3390\/cimb46050243","volume":"46","author":"CN Ashley","year":"2024","unstructured":"Ashley CN, Broni E, Miller WA III. ADAR family proteins: a structural review. Curr Issues Mol Biol. 2024;46(5):3919\u201345.","journal-title":"Curr Issues Mol Biol"},{"key":"995_CR118","doi-asserted-by":"crossref","unstructured":"Sapiro AL, Freund EC, Restrepo L, Qiao H-H, Bhate A, Li Q, et\u00a0al. Zinc finger RNA-binding protein Zn72D regulates ADAR-mediated RNA editing in neurons. Cell reports. 2020;31(7).","DOI":"10.1016\/j.celrep.2020.107654"},{"issue":"40","key":"995_CR119","doi-asserted-by":"publisher","first-page":"24802","DOI":"10.1073\/pnas.2006883117","volume":"117","author":"S Daou","year":"2020","unstructured":"Daou S, Talukdar M, Tang J, Dong B, Banerjee S, Li Y, et\u00a0al. A phenolic small molecule inhibitor of RNase L prevents cell death from ADAR1 deficiency. Proc Natl Acad Sci U S A. 2020;117(40):24802\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"995_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1621585","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Yin F, He Y, Qiao Y, Yan Y, Ma J. Deciphering the mechanistic roles of ADARs in cancer pathogenesis, tumor immune evasion, and drug resistance. Front Immunol. 2025;16:1621585.","journal-title":"Front Immunol"},{"issue":"2","key":"995_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.114615","volume":"29","author":"M Minakuchi","year":"2026","unstructured":"Minakuchi M, Zhang H, Cassel J, Shiromoto Y, Villanueva J, Skordalakes E, et\u00a0al. Identification of ADAR1i-124: the first effective A-to-I RNA editing inhibitor with promising cancer therapeutic potential. iScience. 2026;29(2):114615.","journal-title":"iScience"},{"issue":"9","key":"995_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116151","volume":"44","author":"\u00c1F \u00c1lvarez-Prado","year":"2025","unstructured":"\u00c1lvarez-Prado \u00c1F, Hern\u00e1ndez-Barranco A, Rentsch L, Costa CF, Joyce JA. Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival. Cell Rep. 2025;44(9):116151.","journal-title":"Cell Rep"},{"issue":"39","key":"995_CR123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2210104119","volume":"119","author":"S Suh","year":"2022","unstructured":"Suh S, Choi EH, Raguram A, Liu DR, Palczewski K. Precision genome editing in the eye. Proc Natl Acad Sci U S A. 2022;119(39):e2210104119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"995_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030777","author":"LE Fry","year":"2020","unstructured":"Fry LE, Peddle CF, Barnard AR, McClements ME, MacLaren RE. RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21030777.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"995_CR125","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/mt.2011.98","volume":"19","author":"H Zhang","year":"2011","unstructured":"Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, et\u00a0al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther. 2011;19(8):1440\u20138.","journal-title":"Mol Ther"},{"issue":"4","key":"995_CR126","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317\u201334.","journal-title":"BioDrugs"},{"issue":"32","key":"995_CR127","doi-asserted-by":"publisher","first-page":"25910","DOI":"10.1039\/D5RA03578C","volume":"15","author":"D Senanayake","year":"2025","unstructured":"Senanayake D, Yapa P, Dabare S, Munaweera I. Precision targeting of the CNS: recent progress in brain-directed nanodrug delivery. RSC Adv. 2025;15(32):25910\u201328.","journal-title":"RSC Adv"},{"key":"995_CR128","doi-asserted-by":"crossref","unstructured":"Gernert M, Feja M. Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies. Pharmaceutics. 2020;12(12).","DOI":"10.3390\/pharmaceutics12121134"},{"issue":"7","key":"995_CR129","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40263-022-00930-4","volume":"36","author":"A Lofts","year":"2022","unstructured":"Lofts A, Abu-Hijleh F, Rigg N, Mishra RK, Hoare T. Using the intranasal route to administer drugs to treat neurological and psychiatric illnesses: rationale, successes, and future needs. CNS Drugs. 2022;36(7):739\u201370.","journal-title":"CNS Drugs"},{"key":"995_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27052298","author":"P Mishra","year":"2026","unstructured":"Mishra P, Gupta P, Markowska A, Ghavami S, Markowski J, \u0141os MJ. Advancements in drug delivery systems in glioblastoma therapy. Int J Mol Sci. 2026. https:\/\/doi.org\/10.3390\/ijms27052298.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"995_CR131","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70389","volume":"6","author":"JM Li","year":"2020","unstructured":"Li JM, Huang J, Liao Y, Hu T, Wang CL, Zhang WZ, et\u00a0al. Gene and RNA editing: revolutionary approaches to treating diseases. MedComm. 2020;6(10):e70389.","journal-title":"MedComm"},{"issue":"5","key":"995_CR132","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2174\/156652307782151498","volume":"7","author":"PR Lowenstein","year":"2007","unstructured":"Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther. 2007;7(5):347\u201360.","journal-title":"Curr Gene Ther"},{"issue":"3","key":"995_CR133","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","volume":"37","author":"M Arjomandnejad","year":"2023","unstructured":"Arjomandnejad M, Dasgupta I, Flotte TR, Keeler AM. Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer. BioDrugs. 2023;37(3):311\u201329.","journal-title":"BioDrugs"},{"issue":"1","key":"995_CR134","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.immuni.2020.03.017","volume":"53","author":"G Liu","year":"2020","unstructured":"Liu G, Gack MU. Distinct and orchestrated functions of RNA sensors in innate immunity. Immunity. 2020;53(1):26\u201342.","journal-title":"Immunity"},{"issue":"1","key":"995_CR135","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1038\/s41467-018-05073-z","volume":"9","author":"A Mir","year":"2018","unstructured":"Mir A, Alterman JF, Hassler MR, Debacker AJ, Hudgens E, Echeverria D, et\u00a0al. Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing. Nat Commun. 2018;9(1):2641.","journal-title":"Nat Commun"},{"issue":"9","key":"995_CR136","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/mt.2012.114","volume":"20","author":"CM Treleaven","year":"2012","unstructured":"Treleaven CM, Tamsett TJ, Bu J, Fidler JA, Sardi SP, Hurlbut GD, et\u00a0al. Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies. Mol Ther. 2012;20(9):1713\u201323.","journal-title":"Mol Ther"},{"issue":"4","key":"995_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101602","volume":"33","author":"M Vono","year":"2025","unstructured":"Vono M, Rio TD, Magdaleno E, Loll NR, Jarvis P, Walter C, et\u00a0al. Impact of pre-existing immunity on safety and biodistribution of a single AAV9 vectorintrathecal injection in cynomolgus monkeys. Mol Ther Methods Clin Dev. 2025;33(4):101602.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"995_CR138","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1038\/s41467-025-58778-3","volume":"16","author":"H Costa-Verdera","year":"2025","unstructured":"Costa-Verdera H, Meneghini V, Fitzpatrick Z, Abou Alezz M, Fabyanic E, Huang X, et\u00a0al. AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain. Nat Commun. 2025;16(1):3694.","journal-title":"Nat Commun"},{"issue":"1","key":"995_CR139","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-025-02463-y","volume":"24","author":"Y Yan","year":"2025","unstructured":"Yan Y, Liu S, Wen J, He Y, Duan C, Nabavi N, et\u00a0al. Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications. Mol Cancer. 2025;24(1):251.","journal-title":"Mol Cancer"},{"issue":"2","key":"995_CR140","doi-asserted-by":"publisher","DOI":"10.52965\/001c.24934","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Nguyen LH, Odisho AS, Maxey BS, Pruitt JW, Girma B, et\u00a0al. The antisense oligonucleotide nusinersen for treatment of spinal muscular atrophy. Orthop Rev (Pavia). 2021;13(2):24934.","journal-title":"Orthop Rev (Pavia)"},{"key":"995_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13092167","author":"TG Schreiner","year":"2025","unstructured":"Schreiner TG, Men\u00e9ndez-Gonz\u00e1lez M, Schreiner OD, Ciobanu RC. Intrathecal therapies for neurodegenerative diseases: a review of current approaches and the urgent need for advanced delivery systems. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13092167.","journal-title":"Biomedicines"},{"issue":"2","key":"995_CR142","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40263-022-00899-0","volume":"36","author":"D MacCannell","year":"2022","unstructured":"MacCannell D, Berger Z, Kirschner J, Mercuri E, Farrar MA, Iannaccone ST, et\u00a0al. Restoration of nusinersen levels following treatment interruption in people with spinal muscular atrophy: simulations based on a population pharmacokinetic model. CNS Drugs. 2022;36(2):181\u201390.","journal-title":"CNS Drugs"},{"issue":"3","key":"995_CR143","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41592-019-0323-0","volume":"16","author":"D Katrekar","year":"2019","unstructured":"Katrekar D, Chen G, Meluzzi D, Ganesh A, Worlikar A, Shih YR, et\u00a0al. In vivo RNA editing of point mutations via RNA-guided adenosine deaminases. Nat Methods. 2019;16(3):239\u201342.","journal-title":"Nat Methods"},{"issue":"3","key":"995_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102635","volume":"36","author":"B Kantor","year":"2025","unstructured":"Kantor B, O\u2019Donovan B, Chiba-Falek O. Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: implications for neurodegenerative disease. Mol Ther Nucleic Acids. 2025;36(3):102635.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"995_CR145","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1038\/s41467-025-60155-z","volume":"16","author":"SM Byrne","year":"2025","unstructured":"Byrne SM, Burleigh SM, Fragoza R, Jiang Y, Savva Y, Pabon R, et\u00a0al. An engineered U7 small nuclear RNA scaffold greatly increases ADAR-mediated programmable RNA base editing. Nat Commun. 2025;16(1):4860.","journal-title":"Nat Commun"},{"issue":"10","key":"995_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/cells12101443","volume":"12","author":"T Hosaka","year":"2023","unstructured":"Hosaka T, Tsuji H, Kwak S. Roles of aging, circular RNAs, and RNA editing in the pathogenesis of amyotrophic lateral sclerosis: potential biomarkers and therapeutic targets. Cells. 2023;12(10):1443.","journal-title":"Cells"},{"issue":"sup1","key":"995_CR147","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/15476286.2021.1983288","volume":"18","author":"HM Khosravi","year":"2021","unstructured":"Khosravi HM, Jantsch MF. Site-directed RNA editing: recent advances and open challenges. RNA Biol. 2021;18(sup1):41\u201350.","journal-title":"RNA Biol"},{"issue":"6","key":"995_CR148","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1261\/rna.058271.116","volume":"23","author":"E Picardi","year":"2017","unstructured":"Picardi E, Horner DS, Pesole G. Single-cell transcriptomics reveals specific RNA editing signatures in the human brain. RNA. 2017;23(6):860\u20135.","journal-title":"RNA"},{"issue":"1","key":"995_CR149","doi-asserted-by":"publisher","first-page":"12145","DOI":"10.1038\/ncomms12145","volume":"7","author":"D Harjanto","year":"2016","unstructured":"Harjanto D, Papamarkou T, Oates CJ, Rayon-Estrada V, Papavasiliou FN, Papavasiliou A. RNA editing generates cellular subsets with diverse sequence within populations. Nat Commun. 2016;7(1):12145.","journal-title":"Nat Commun"},{"issue":"3","key":"995_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/biom12030465","volume":"12","author":"K Karagianni","year":"2022","unstructured":"Karagianni K, Pettas S, Christoforidou G, Kanata E, Bekas N, Xanthopoulos K, et\u00a0al. A systematic review of common and brain-disease-specific RNA editing alterations providing novel insights into neurological and neurodegenerative disease manifestations. Biomolecules. 2022;12(3):465.","journal-title":"Biomolecules"},{"key":"995_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.102085","author":"K Karagianni","year":"2024","unstructured":"Karagianni K, Bibi A, Mad\u00e9 A, Acharya S, Parkkonen M, Barbalata T, et\u00a0al. Recommendations for detection, validation, and evaluation of RNA editing events in cardiovascular and neurological\/neurodegenerative diseases. Mol Ther Nucleic Acids. 2024. https:\/\/doi.org\/10.1016\/j.omtn.2023.102085.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"995_CR152","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.ymthe.2023.01.005","volume":"31","author":"BJ Booth","year":"2023","unstructured":"Booth BJ, Nourreddine S, Katrekar D, Savva Y, Bose D, Long TJ, et\u00a0al. RNA editing: expanding the potential of RNA therapeutics. Mol Ther. 2023;31(6):1533\u201349.","journal-title":"Mol Ther"}],"container-title":["Cellular & Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-026-00995-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00995-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00995-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:02:19Z","timestamp":1786348939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-026-00995-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":152,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["995"],"URL":"https:\/\/doi.org\/10.1186\/s11658-026-00995-9","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"130"}}